



HAL
open science

Epigenotype-phenotype correlations in Silver-Russell syndrome

Emma L Wakeling, Sayeda Abu Amero, Marielle Alders, Jet Blied, Elizabeth Forsythe, Shraddha Kumar, Derek H Lim, Fiona Macdonald, Deborah J Mackay, Eamonn R Maher, et al.

► **To cite this version:**

Emma L Wakeling, Sayeda Abu Amero, Marielle Alders, Jet Blied, Elizabeth Forsythe, et al.. Epigenotype-phenotype correlations in Silver-Russell syndrome. *Journal of Medical Genetics*, 2010, 47 (11), pp.760. 10.1136/jmg.2010.079111 . hal-00557400

HAL Id: hal-00557400

<https://hal.science/hal-00557400>

Submitted on 19 Jan 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Epigenotype-phenotype correlations in Silver-Russell syndrome

Wakeling EL¹, Abu Amero S², Alders M³, Blik J³, Forsythe E¹, Kumar S¹, Lim DH⁴
MacDonald F⁵, Mackay DJ^{6,7}, Maher ER⁴, Moore GE², Poole RL^{6,7}, Price SM⁸, Tangeraas T⁹,
Turner CLS⁷, Van Haelst MM¹⁰, Willoughby C¹¹, Temple IK^{7,12}, Cobben JM¹³

¹North West Thames Regional Genetic Service (Kennedy-Galton Centre), North West London Hospitals NHS Trust, Harrow, UK;

²Institute of Child Health, University College London, London, UK;

³Department of Clinical Genetics, Academic Medical Centre, Amsterdam, The Netherlands;

⁴Centre for Rare Diseases and Personalised Medicine and School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, and West Midlands Genetics Service, Birmingham Women's Hospital, Birmingham, UK

⁵Department of Medical and Molecular Genetics, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, and West Midlands Genetics Service, Birmingham Women's Hospital, Birmingham, UK;

⁶Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury, UK;

⁷Division of Human Genetics, University of Southampton, School of Medicine, Southampton, UK;

⁸Department of Clinical Genetics, Northampton General Hospital, Northampton, UK

⁹Division of Pediatrics, Oslo University Hospital, Rikshospitalet, Oslo, Norway

¹⁰Department of Medical Genetics, University Medical Center, Utrecht, The Netherlands;

¹¹DNA Laboratory, Medical Genetics Unit, St Georges Hospital, London, UK;

¹²Wessex Clinical Genetics Service, Southampton University Hospitals Trust, Southampton, SO16 5YA, UK

¹³Department of Pediatric Genetics, Emma Kinderziekenhuis AMC, Amsterdam, The Netherlands

Correspondence to:

Dr E Wakeling, North West Thames Regional Genetic Service (Kennedy-Galton Centre),
Level 8V, North West London Hospitals NHS Trust, Watford Rd, Harrow, Middlesex, HA1
3UJ, UK

Email: e.wakeling@imperial.ac.uk

Tel: 020 8869 2795

Fax: 020 8869 3106

ABSTRACT

Background: Silver-Russell syndrome (SRS) is characterised by intrauterine growth restriction, poor postnatal growth, relative macrocephaly, triangular face and asymmetry. Maternal uniparental disomy (mUPD) of chromosome 7 and hypomethylation of the imprinting control region (ICR) 1 on chromosome 11p15 are found in around 5-10% and up to 60% of patients with SRS, respectively. As many features are non-specific, diagnosis of SRS remains difficult. Studies of patients in whom the molecular diagnosis is confirmed therefore provide valuable clinical information regarding the condition.

Methods: We undertook a detailed, prospective study of 64 patients with mUPD7 (n=20) or ICR1 hypomethylation (n=44).

Results and conclusions: The considerable overlap in clinical phenotype makes it difficult to distinguish these two molecular subgroups reliably. ICR1 hypomethylation patients were more likely to be scored as 'classical' SRS. Asymmetry, fifth finger clinodactyly and congenital anomalies were more commonly seen with ICR1 hypomethylation, whereas learning difficulties and referral for speech therapy were more likely with mUPD7. Myoclonus-dystonia has been reported previously in one mUPD7 patient. We report mild movement disorders in three further cases. No correlation was found between clinical severity and level of ICR1 hypomethylation. Use of assisted reproductive technology in association with ICR1 hypomethylation seems increased compared with the general population. ICR1 hypomethylation was also observed in affected siblings though recurrence risk remains low in the majority of cases. Overall, a wide range in severity was observed, particularly with ICR1 hypomethylation. We therefore recommend a low threshold for investigation of patients with features suggestive, but not typical, of SRS.

Key words

Silver Russell syndrome; mUPD7; 11p15 hypomethylation; phenotype; imprinting

INTRODUCTION

Silver-Russell syndrome (SRS) is characterised by intrauterine growth restriction (IUGR), poor postnatal growth, relative macrocephaly, triangular facial appearance, asymmetry of the face and/or limbs and fifth finger clinodactyly^{1,2,3}. In 1999 Price *et al.* studied a cohort of 50 SRS patients and suggested criteria for diagnosis⁴. However, the relatively non-specific features of SRS present a continuing challenge to clinical diagnosis and to definition of its true spectrum and natural history.

SRS is genetically heterogeneous. The first molecular abnormality identified in a significant proportion of patients was maternal uniparental disomy for chromosome 7 (mUPD7)⁵. Evidence suggests this is present in around 5-10% of cases^{6,7}. More recently, abnormalities of chromosome 11p15 have been described. Chromosome 11p15 contains imprinted genes implicated in fetal growth, controlled by two imprinting control regions (ICRs): the telomeric ICR1 regulates expression of *IGF2* and *H19*; the centromeric ICR2 controls expression of *CDKN1C*, *LIT1 (KCNQ10T1)* and other genes. Disturbances of this region are associated with the overgrowth disorder Beckwith-Wiedemann syndrome (BWS). Identification of maternally-derived chromosome 11p15 duplications in growth-restricted individuals, some with features of SRS^{8,9}, led to further investigation of this region in SRS.

In 2005, Gicquel *et al.* reported loss of paternal methylation at ICR1 in five out of nine patients with typical SRS features¹⁰. This was associated with biallelic expression of *H19* and down-regulated expression of the growth promoter *IGF2*. Subsequent studies suggest that up to 60% of SRS patients have ICR1 methylation defects, depending on the clinical criteria used for selection of cases^{7,11}. To date only one patient has been reported with a maternally derived duplication restricted to ICR2¹².

Initial reports of a relatively mild phenotype in association with mUPD7¹³ have been corroborated by more recent comparisons with ICR1 hypomethylation patients^{11,14,15}. However, retrospective analysis of all mUPD7 patients published to date, concluded that mUPD7 could not be reliably differentiated from ICR1 hypomethylation on clinical grounds alone¹⁶. Clinical studies of several patient cohorts with ICR1 hypomethylation^{11,14,15,16,17,18,19} demonstrate in the majority a typical SRS phenotype comprising IUGR, postnatal short stature, characteristic craniofacial features and frequently asymmetry^{11,14,15,18}. A minority of patients have less typical features^{17,20,21}. Correlation between the level of ICR1 hypomethylation and the severity of SRS phenotype has been reported in several studies^{10,14,17,20}, though the majority of these have relied on retrospective data which may be limited and/or incomplete. Comparisons of

patients with ICR1 hypomethylation and mUPD7 are restricted by the small numbers of patients in the latter group.

We report a prospective study of clinical features among 64 patients with a positive diagnosis of SRS: 20 with mUPD7 and 44 with 11p15 hypomethylation. Findings in patients with mUPD and 11p15 methylation abnormalities were compared, allowing features more characteristic of each group to be defined. We also sought evidence of correlation between the level of 11p15 hypomethylation and severity of clinical features.

METHODS

Patients

64 patients with either mUPD7 or 11p15 hypomethylation were ascertained, following referral to diagnostic laboratories within the UK and the Netherlands for investigation of a possible diagnosis of SRS, growth restriction or asymmetry. Molecular reports were obtained for all patients confirming positive diagnosis. Patients and their parents attended an appointment during which clinical information was recorded on a standard proforma, and the patient examined and measured. To preserve consistency in recording of data, all patients were seen by one or more of a small group of experienced clinical geneticists (EW, MVH, DL, SP, CT, KT, JMC) with a special interest in SRS. Subsequently, all data and clinical pictures were evaluated by one coordinating clinical geneticist (EW). Additional information was also obtained from the hospital notes. Informed consent was obtained from all patients and/or their parents and the study was approved by the Trent Research Ethics Committee.

Molecular analysis

DNA methylation of *KCNQ1OT1* and *H19* was measured in the Academic Medical Centre, University of Amsterdam, Netherlands (laboratory 1, 21 patients), and in the UK, the Wessex Regional Genetics Laboratory (laboratory 2, 19 patients), West Midlands Genetics Laboratory (laboratory 3, four patients) and South West Thames Molecular Genetics Diagnostic Laboratory (laboratory 4, three patients).

Methylation-specific multiplex ligation-mediated PCR analysis (MS-MLPA) was the first-line test in laboratories 3 and 4, and the second-line testing in laboratories 1 and 2. The SALSA MLPA kit ME-030 (MRC Holland) was used according to the manufacturer's instructions²². In laboratories 1, 2 and 4 the cut-off for diagnosis of an epigenetic anomaly was a peak height ratio ≥ 1.3 at two or more adjacent probes, and in laboratory 3 the cut-off was ≥ 1.25 . Among 75

normal controls such a ratio was not observed at two or more adjacent probes²².

In laboratory 1, methylation-specific high-resolution melt analysis (HRM-A) was used as first-line testing, as described²³. Hypomethylation was determined by visual comparison of case and control samples, an abnormal peak shape being absent from 45 normal controls. In laboratory 2, methylation-specific PCR (MS-PCR), was used as first-line testing, as described²⁴. A peak height ratio of 1.3 was taken as evidence of hypomethylation, such a ratio not being seen among 120 normal controls. For both HRM-A and MS-PCR, genomic DNA was bisulphite-modified using the EZ and EZ Gold DNA modification kits (Zymo Research) according to the manufacturer's instructions. In all laboratories, testing for uniparental disomy of chromosome 11 was performed by standard analysis of microsatellite markers including D11S2071, D11S4046, D11STH, D11S1318, and D11SHBB.

Testing for uniparental disomy of chromosome 7 was performed by microsatellite analysis in laboratories 1-4 (13 patients) and a further six NHS service laboratories in the UK (8 patients). In laboratories 1-4, a minimum of six markers were used, including at least two each on 7p and 7q. Exclusion of mUPD7 required evidence of biparental inheritance at two or more markers, whereas a positive diagnosis required evidence of uniquely maternal inheritance of two or more markers. In the remaining laboratories, data from diagnostic reports confirmed that a minimum of three microsatellite markers were tested, with positive diagnosis requiring evidence of uniquely maternal inheritance of at least two markers.

Clinical scoring

Patients were scored using the five key criteria (birth weight ≤ -2 SD from mean; poor postnatal growth ≤ -2 SD from mean; preservation of OFC; classic facial features; asymmetry) suggested by Price *et al.*⁴. Patients in our study found to have at least four of these features were described as having 'classical' SRS. Limb asymmetry was scored as present if there was ≥ 1 cm arm and/or leg length difference; facial asymmetry was scored subjectively.

Laboratory staff were blind to the clinical scoring/ phenotype of the patients tested. Scoring was carried out by one of the investigators not involved in examination of the patients and also blind to the methylation index results (SK).

Statistical analysis

Statistical comparisons between the two molecular subgroups were made using Fisher's exact test, the unpaired t-test and the Mann-Whitney test, as appropriate. Correlation of methylation index with a number of clinical parameters was analysed using Pearson correlation,

Spearman's rank correlation and the unpaired t-test, as appropriate. Statistical significance was set at ≤ 0.05 .

RESULTS

A total of 64 patients were included in this study: 44 with 11p15 methylation abnormalities and 20 with mUPD7. The mean age in the two groups was similar: 6.3 years (range 0.8-26.8) for ICR1 hypomethylation; 7.3 years (range 1.3-17.9) for mUPD7.

The majority of patients with abnormal 11p15 methylation had abnormalities restricted to ICR1. One patient reported previously was known to have mosaic mUPD11²⁵ and two more had maternal duplication of ICR1 and ICR2 (see supplementary text and figure 3 online). All three of these patients have typical SRS features.

In one family an affected brother and sister were found to have ICR1 hypomethylation. Their parents and two other unaffected siblings had normal methylation patterns.

Clinical score

61% ICR1 hypomethylation patients had at least four of the five key features, compared with just 20% mUPD7 patients ($p=0.003$). The mean scores for patients with ICR1 hypomethylation and mUPD7 were 3.7 and 3.0 respectively. However, the greatest range in severity was associated with ICR1 hypomethylation (range 2-5, compared with 2-4 for mUPD7). Four (9%) patients with ICR1 hypomethylation and five (25%) with mUPD7 had just one or two of these features. Of these, four were referred for testing on the basis of asymmetry (hemihypotrophy) and five due to pre- and/or postnatal growth failure.

Two patients with normal growth parameters were referred for investigation of asymmetry. One patient with mUPD7 had typical facial features but birth weight -1.53 SD and height -1.3 SD at 7 years. Another patient with 11p15 hypomethylation had 5th finger clinodactyly but no other features of SRS, with birth weight -1.33 SD and height +0.2 SD at 10 months.

The frequency of clinical features found in the two molecular subgroups is summarised in Table 1.

Growth parameters

From maternal recollection, IUGR was suspected in 89% cases with ICR1 hypomethylation and 70% with mUPD7 ($p=0.08$). In both groups the average gestation at which IUGR was

detected was 23 weeks, probably reflecting the fact that most women have anomaly scans at around this stage of pregnancy.

Overall, 78% of patients had a birth weight ≤ -2 SDS with a wide range, particularly among ICR1 hypomethylation patients (range -4.88 to -0.5 SD, mean -2.49 SD). Patients with mUPD7 had a mean birth weight of -2.24 SD (range -3.29 to -1.29 SD). Birth weight was therefore more frequently ≤ -2 SDS with ICR1 hypomethylation whereas height at examination was more frequently ≤ -2 SDS with mUPD7.

In total 30% of patients had received growth hormone. Insufficient retrospective data were available to analyse the difference in the effect of growth hormone treatment. In those patients not treated with growth hormone, ICR1 hypomethylation patients (53%) were less likely to show postnatal reduction in height SDS than those with mUPD7 (78%) ($p=0.26$). Eight patients had reached their final height, of which five had been treated with growth hormone (see supplementary table online). Numbers were too small to allow meaningful analysis of the effect of growth hormone on final height.

Developmental delay

Global developmental delay was described in 34% cases. Severe delay was uncommon, being described in only two children, both with ICR1 hypomethylation. One was diagnosed following investigation for asymmetry. However, he was felt to be very atypical for SRS, his growth parameters were normal and further investigation is ongoing to look for an additional cause for his problems. The other had suffered a cardiac arrest at nine months following repair of a ventricular septal defect. If these two children are excluded from the analysis, moderate delay was seen in one (2%) patient with ICR1 hypomethylation and two (10%) with mUPD7. In the remainder, developmental problems were mild. In those patients without global delay, gross motor delay was still common, with mean age at walking of around 20 months in both groups.

Behavioural problems were infrequent and mild. Three children (one with mUPD7 and two with ICR1 hypomethylation) were reported by their parents as being hyperactive. Only one child had been referred for further assessment for behavioural problems.

Congenital anomalies

Major congenital abnormalities were markedly more common in those patients with ICR1 hypomethylation (Table 2). Camptodactyly was seen in 19% overall and appears to gradually progress in severity with age. Restriction of movement in other joints was confined to patients with ICR1 hypomethylation. Only upper limbs were affected, with four patients having limited

elbow extension bilaterally/unilaterally and one having bilateral reduction of shoulder movements.

Hypoglycaemia

Excessive sweating was reported by 67% of parents. This may have represented hypoglycaemia, but in most cases had not been formally investigated. Since there was no significant difference in the frequency of documented evidence of hypoglycaemia in either group, it is unlikely to account for the difference in rate of global developmental delay.

Feeding difficulties

Feeding difficulties were scored according to severity (1= normal, 2= mild, 3= frequent/long feeds, 4= prolonged nasogastric feeds, 5= gastrostomy insertion). The average score for mUPD7 was slightly higher than that for ICR1 hypomethylation (4.7 with mean SD 1.3 and 3.4 with mean SD 1.4 respectively), though this did not reach statistical significance ($p=0.48$).

Movement disorders

Intriguingly, one patient with mUPD7, aged 14.9 years, was described as having intermittent episodes of head shaking. Another patient, aged 14.2 years, has a slight tremor affecting his left arm. One further mUPD7 patient had myoclonic jerks in infancy (from 3 weeks to one year), which had subsequently resolved. No patients with ICR1 hypomethylation had similar problems.

Facial features

Figures 1 and 2 show facial features for many of the patients with ICR1 hypomethylation and mUPD7 included in this study. The photographs illustrate how facial features become less striking with age. Due to difficulties obtaining early pictures and growth data from many of the older patients, clinical features such as frontal bossing, triangular face and micrognathia were scored according to the appearance of the patient at examination (Table 1). Additionally, data were analysed for triangular facies and frontal bossing in those patients under five years at examination. As expected, this showed increased frequency of specific features at this age (triangular face in 67% ICR1 hypomethylation and 100% mUPD7; frontal bossing in 81% ICR1 hypomethylation and 67% mUPD7).

Correlation with methylation index

Data on methylation index was available for 29 of the 44 patients with ICR1 hypomethylation. Clinical score, birth weight SDS, postnatal height SDS, severity of feeding difficulties and the presence of developmental delay, asymmetry and/or congenital anomalies were all analysed for correlation with level of ICR1 hypomethylation. No evidence was found for correlation between the level of ICR1 hypomethylation and clinical severity (Table 3).

Assisted reproductive technology (ART)

All five cases conceived as a result of in vitro fertilisation (IVF) treatment, including one via ovum donation and one via intracytoplasmic sperm injection (ICSI), were within the ICR1 hypomethylation group. However, this difference between the groups did not reach statistical significance.

DISCUSSION

Clinical diagnosis of SRS remains difficult as many of its features are non-specific, diagnostic criteria are not universally agreed, and features are most striking in early childhood, making assessment of older patients difficult. By collecting clinical data from patients with a positive molecular diagnosis of SRS, we were able to include patients irrespective of whether their referring physician felt them clinically 'typical'. This reduced reporting bias. In contrast to previously published studies, our data were gathered prospectively by a small number of experienced geneticists, allowing both detailed and consistent analysis of the phenotype.

Several scoring systems for clinical diagnosis of SRS have been proposed^{4,11,15}. Most recently Bartholdi *et al.*, developed criteria to score 168 patients with suspected SRS¹⁵, which were fulfilled by all patients found to have ICR1 hypomethylation, but only seven out of 10 patients with mUPD7. These criteria could not be applied in our study since data such as birth OFC and length were frequently unavailable, and the early age of many participants precluded scoring for normal cognitive development (defined as attending regular school). We therefore used the criteria suggested by Price *et al.*⁴, since complete data was available for scoring in all patients. However, we recognise that these criteria do not include feeding difficulties, which are a major feature of this condition.

Clinical features in mUPD7 and ICR1 hypomethylation

Our study included sufficient patients with mUPD7 to allow statistical comparison of features with ICR1 hypomethylation cases. Consistent with other studies^{11,14,15,17,18,19}, we found that

61% of patients with ICR1 hypomethylation had ‘classic’ features of SRS, compared with only 20% of mUPD7 patients.

ICR1 hypomethylation patients were less likely to show postnatal reduction in height SDS than those with mUPD7, although numbers were too small to reach statistical significance. Binder *et al.* showed that children with mUPD7 have a significantly higher birth length but lose height SDS postpartum, whereas 11p15 hypomethylation patients show no change in height SDS¹⁹. The same study noted a trend towards more height gain on growth hormone therapy in children with mUPD7 than those with ICR1 hypomethylation¹⁹. In our study, insufficient data were available to test this observation. However, two adults with ICR1 hypomethylation who had been treated with growth hormone achieved final heights well within the normal range. The possible differential effect of growth hormone in these two subgroups is an important clinical question which deserves further detailed and prospective investigation.

Asymmetry was significantly more common with ICR1 hypomethylation. This finding is in keeping with previous reports^{4,13,15,16} and may reflect mosaicism for hypomethylation at the tissue level.

We found psychomotor retardation in approximately one third of SRS patients, in keeping with previous observations²⁶. Patients with mUPD7 were more likely to have delayed development and to have a statement of education. Global delay was mostly mild, though moderate delay was more common with mUPD7. Speech delay and referral for speech therapy were more common with mUPD7, as reported in previous studies¹³. This finding has been linked to the absence of paternal *FOXP2* expression, as seen in other patients with developmental verbal dyspraxia²⁷. Early motor delay was also relatively common in both groups and may result from a combined effect of low muscle bulk and relatively large head size in infancy.

Feeding difficulties are well recognised as a major feature of SRS²⁸. Parents of children from both groups in this study frequently commented on their lack of interest in sucking and absence of hunger from birth.

In the SRS cohort of Price *et al.*, 22% had generalised camptodactyly⁴. It has been hypothesised that this is specific to patients with ICR1 hypomethylation¹⁷. Bruce *et al.*, reported several patients with ICR1 defects and joint contractures (including limited elbow extension) and/or other skeletal abnormalities¹⁴. In our cohort, limited elbow extension was seen in four patients. Interestingly, one patient was found to have radial hypoplasia. Although this feature is not usually associated with SRS, at least one other patient with ICR1 hypomethylation has been described with thumb hypoplasia¹⁴.

In common with other studies¹⁴, major congenital anomalies were significantly more common in patients with 11p15 involvement. Overall, major congenital anomalies appear to be much more suggestive of, though not exclusive to, ICR1 hypomethylation.

Importantly, we observed two teenage patients with mUPD7 and mild movement disorders; a further patient had a history of myoclonic jerks in infancy. This is particularly interesting in light of a recent report of myoclonus-dystonia in a patient with mUPD7²⁹. Myoclonus-dystonia typically presents before adulthood with mild dystonia (such as cervical dystonia or writer's cramp) and/or myoclonic jerks. The disorder is associated with paternally derived mutations in the imprinted gene ϵ -sarcoglycan (*SGCE*) gene on chromosome 7q21. It may not previously have been noted with mUPD7 as symptoms are relatively mild and may start in later childhood. In addition, other genes may modify the development of this condition, as has been noted in dystonia due to *DYT1* and *DYT6* mutations³⁰.

The 'classical' facial features of SRS (triangular-shaped face, frontal bossing, downturned corners of the mouth and micrognathia) were apparent in many but not all patients in both groups. One retrospective study suggested a higher frequency of macrocephaly and frontal bossing in patients with ICR1 hypomethylation, and a higher incidence of triangular facies with mUPD7¹⁶. These previous observations are supported by our analysis of facial features in patients under five years.

It is well recognised that patients with BWS due to UPD and imprinting defects of ICR1 are at increased risk of embryonal tumours³¹. However, to date none of the SRS patients with hypomethylation of *H19* reported in this study have developed tumours. Taken together with data from previous studies^{11,14,15,17,20}, there is currently no evidence for an increased childhood tumour risk in patients with ICR1 hypomethylation.

Variation in severity of features

While most studies have found no evidence for ICR1 hypomethylation in cohorts of patients with isolated pre- or postnatal growth retardation^{11,14,15,18}, incomplete SRS phenotype has been described with ICR1 methylation abnormality^{17,20,21}. Patients presenting primarily with hemihypotrophy or with mild pre- and/or postnatal growth failure therefore form part of the spectrum of ICR1 hypomethylation.

The range of phenotypic severity has been linked to the level of ICR1 hypomethylation. Bruce *et al.* reported correlation of severe ICR1 hypomethylation with the presence of asymmetry, micrognathia and congenital anomalies¹⁴. It was suggested that 35% of the variation in clinical severity could be explained by the level of *H19* hypomethylation.

However, we found no statistical correlation between methylation index and degree of clinical severity in 29 patients studied.

Other factors may also influence the degree to which ICR1 hypomethylation patients are affected. Methylation status in all our patients was analysed in DNA from blood lymphocytes, but clinical severity may reflect tissue-level mosaicism. Furthermore, Bartholdi *et al.* described selective hypomethylation of either *H19* or *IGF2* in 11/42 and 3/42 patients, respectively¹⁵, associated with amelioration of phenotype. We had insufficient molecular data to perform a similar analysis in this study. Another potential explanation for the clinical variation may be hypomethylation of multiple imprinted loci (HIL) in some patients³². Fourteen patients in this study were investigated for HIL, of whom three showed additional methylation anomalies (DM, personal communication); the significance of this remains to be determined.

Assisted reproductive technology

Several recent studies have reported an increased frequency of ART conceptions in children with BWS or Angelman syndrome (AS)³³. These findings are consistent with reports of imprinting defects in animal studies following *in vivo* embryo culture. Evidence also exists for an increased frequency of ART in association with SRS³⁴. The general rate of ART is 1-3%, of which low birth weight is a recognized complication³⁵. In this study, all five patients conceived as a result of ART had ICR1 hypomethylation (11% of this group), supporting an association between ART and imprinting defects in SRS. There is evidence that the increased incidence of BWS and AS after ART is associated with fertility problems³⁶, but SRS patients were not included in this study. Interestingly, the reported rate of infertility (taking over one year to conceive) in our two subgroups was similar (18% with ICR hypomethylation and 20% with mUPD7). This suggests that ART may also have a direct effect. However, much larger and more rigorous studies are required to investigate this further.

Familial recurrence

The vast majority of cases of SRS are non-familial, but a few exceptions are reported in the literature, notably those described recently by Bartholdi *et al.*¹⁴. One recurrence within affected siblings was found in our present study. Microsatellite analysis in the family was inconsistent with an imprinting centre defect within 11p15 (DM, personal communication). In another study, methylation analysis in sperm from a patient with 11p15 hypomethylation showed a normal sperm-specific methylation pattern with full methylation at two loci within this region¹⁹. These findings suggest that epimutation is reversed in the male germline. An

alternative explanation for recurrence, consistent with these findings, is an inherited alteration of a trans-acting factor responsible for maintenance of the imprint post-fertilization.

Adult patients

Only eight of our cohort had reached post-pubertal age, possibly reflecting several factors: molecular diagnosis of SRS has only recently become widely available; SRS cases may get lost to follow-up; and the characteristic features become less noticeable with time. It has been hypothesised by Barker³⁷ that the epidemiological association between poor fetal and infant growth and the subsequent development of type 2 diabetes, results from the effects of poor nutrition in early life, which in turn produces permanent changes in glucose-insulin metabolism. However, there is, as yet, no evidence to suggest that SRS patients are at increased risk of developing type 2 diabetes or other metabolic problems in adulthood. In this study, detailed endocrine work-up had only been carried out in one adult patient (at 26 years). Longer term, systematic endocrine follow-up, looking for evidence of metabolic abnormalities in SRS patients with mUPD7, ICR1 hypomethylation and idiopathic SRS will be important.

Conclusions

This study is restricted to SRS patients with known molecular abnormalities. In around 30% patients with a clinical diagnosis of SRS, the underlying molecular defect is unknown. Ideally, molecular karyotype analysis should be carried out in patients where the diagnosis of SRS is considered but mUPD7 and ICR1 hypomethylation have been excluded. Recent studies have shown that a small proportion of such patients have cryptic chromosome rearrangements³⁸. However, they are often labelled as ‘mild’ SRS, and this reinforces the importance of careful clinical assessment to try to reduce the heterogeneity of patients with idiopathic SRS.

On the other hand, application of a strict scoring system risks missing patients with either mUPD7 or a mild phenotype associated with ICR1 hypomethylation. Only 61% of hypomethylation 11p15 and 20% of mUPD7 cases in our study would have been diagnosed as ‘classical’ SRS according to the criteria of Price *et al.*⁴. No single clinical feature was present in all cases and even low birth weight in only 78% overall. We would therefore recommend a low threshold for investigation of SRS, and, since it is difficult to differentiate between mUPD7 and ICR1 hypomethylation on the basis of clinical features alone, testing for both should be carried out.

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in JMG and any other BMJPG products and sublicences such use and exploit all subsidiary rights, as set out in our licence (<http://group.bmj.com/products/journals/instructions-for-authors/licence-forms>).

Acknowledgements: We would like to thank all the parents and children in the UK and The Netherlands who have participated in the study. We are grateful to the many clinicians who have helped recruit patients to the study and provided clinical data. Hillary Bullman and Margaret Lever from Wessex Regional Genetics laboratory tested many of the samples from patients in UK and provided useful feedback on the paper. We would also like to thank Paul Bassett for his clear statistical advice.

Funding: This study was supported by a grant from the Child Growth Foundation.

Competing interests: None

REFERENCES

1. **Silver HK**, Kiyasu W, George J, Deamer WC. Syndrome of congenital hemihypertrophy, shortness of stature, and elevated urinary gonadotropins. *Pediatrics* 1953;**12**:368-76.
2. **Russell A**. A syndrome of intra-uterine dwarfism recognizable at birth with cranio-facial dysostosis, disproportionately short arms, and other anomalies (5 examples). *Proc R Soc Med* 1954;**47**:1040-4.
3. **Wollmann HA**, Kirchner T, Enders H, Preece MA, Ranke MB. Growth and symptoms in Silver-Russell syndrome: review on the basis of 386 patients. *Eur J Pediatr* 1995;**154**:958-68.
4. **Price SM**, Stanhope R, Garrett C, Preece MA, Trembath RC. The spectrum of Silver-Russell syndrome: a clinical and molecular genetic study and new diagnostic criteria. *J Med Genet* 1999;**36**:837-42.
5. **Kotzot D**, Schmitt S, Bernasconi F, Robinson WP, Lurie IW, Ilyina H, Krajewska-Walasek, Lurie IW, Otten BJ, Schoenle E, Tariverdian G, Schinzel A. Uniparental disomy 7 in Silver-Russell syndrome and primordial growth retardation. *Hum Mol Genet* 1995;**4**:583-7.
6. **Abu-Amero S**, Monk D, Frost J, Preece M, Stanier P, Moore GE. The genetic aetiology of Silver-Russell syndrome. *J Med Genet* 2008;**45**:193-9.
7. **Abu-Amero S**, Wakeling EL, Preece M, Whittaker J, Stanier P, Moore GE. Epigenetic signatures of Silver-Russell syndrome. *J Med Genet* 2010;**47**:150-4.
8. **Fisher AM**, Thomas NS, Cockwell A, Stecko O, Kerr B, Temple IK, Clayton P. Duplications of chromosome 11p15 of maternal origin result in a phenotype that includes growth retardation. *Hum Genet* 2002; **111**: 290-6.
9. **Eggermann T**, Meyer E, Obermann C, Heil I, Schüler H, Ranke MB, Eggermann K, Wollmann HA. Is maternal duplication of 11p15 associated with Silver-Russell syndrome? *J Med Genet* 2005;**42**:e26.
10. **Gicquel C**, Rossignol S, Cabrol S, Houang M, Steunou V, Barbu V, Danton F, Thibaud N, Le Merrer M, Burglen L, Bertrand A-M, Netchine I, Le Bouc Y. Epimutation of the telomeric imprinting center region on chromosome 11p15 in Silver-Russell syndrome. *Nat Genet* 2005;**37**:1003-7.
11. **Netchine I**, Rossignol S, Dufourg MN, Azzi S, Rousseau A, Perin L, Houang M, Steunou V, Esteva B, Thibaud N, Demay MC, Danton F, Petriczko E, Bertrand AM, Heinrichs C, Carel JC, Loeuille GA, Pinto G, Jacquemont ML, Gicquel C, Cabrol S, Le Bouc Y. 11p15 imprinting center region 1 loss of methylation is a common and specific cause of typical

- Russell-Silver syndrome: clinical scoring system and epigenetic-phenotypic correlations. *J Clin Endocrinol Metab* 2007;**92**:3148-54.
12. **Schönherr N**, Meyer E, Roos A, Schmidt A, Wollmann HA, Eggermann T. The centromeric 11p15 imprinting centre is also involved in Silver-Russell syndrome. *J Med Genet* 2007 Jan;44(1):59-63.
 13. **Hannula K**, Kere J, Pirinen S, Holmberg C, Lipsanen-Nyman M. Do patients with maternal uniparental disomy for chromosome 7 have a distinct mild Silver-Russell phenotype? *J Med Genet* 2001;**38**:273-8.
 14. **Bruce S**, Hannula-Jouppi K, Peltonen J, Kere J, Lipsanen-Nyman M. Clinically distinct epigenetic subgroups in Silver-Russell syndrome: the degree of H19 hypomethylation associates with SRS phenotype severity and genital and skeletal anomalies. *J Clin Endocrinol Metab* 2008; **94**:579-87.
 15. **Bartholdi D**, Krajewska-Walasek M, Ounap K, Gaspar H, Chrzanowska KH, Ilyana H, Kayserili H, Lurie IW, Schinzel A, Baumer A. Epigenetic mutations of the imprinted IGF2-H19 domain in Silver-Russell syndrome (SRS): results from a large cohort of patients with SRS and SRS-like phenotypes. *J Med Genet* 2009;**46**:192-7.
 16. **Kotzot D**. Maternal uniparental disomy 7 and Silver-Russell syndrome - clinical update and comparison with other subgroups. *Eur J Med Genet* 2008;**51**:444-51.
 17. **Blijk J**, Terhal P, van den Bogaard MJ, Maas S, Hamel B, Salieb-Beugelaar G, Simon M, Letteboer T, van der Smagt J, Kroes H, Mannens M. Hypomethylation of the H19 gene causes not only Silver-Russell syndrome (SRS) but also isolated asymmetry or an SRS-like phenotype. *Am J Hum Genet* 2006;**78**:604-14.
 18. **Schönherr N**, Meyer E, Eggermann K, Ranke MB, Wollmann HA, Eggermann T. (Epi)mutations in 11p15 significantly contribute to Silver-Russell syndrome: but are they generally involved in growth retardation? *Eur J Med Genet* 2006 Sep;49(5):414-8.
 19. **Binder G**, Seidel AK, Martin DD, Schweizer R, Schwarze CP, Wollmann HA, Eggermann T, Ranke M. The endocrine phenotype in Silver-Russell syndrome is defined by the underlying epigenetic alteration. *J Clin Endocrinol Metab* 2008;**93**:1402-7.
 20. **Zeschnigk M**, Albrecht B, Buiting K, Kanber D, Eggermann T, Binder G, Gromoll J, Prott E-C, Seland S, Horsthemke B. IGF2/H19 hypomethylation in Silver-Russell syndrome and isolated hemihypoplasia. *Eur J Hum Genet* 2008;**16**:328-34.
 21. **Eggermann T**, Gonzalez D, Spengler S, Arslan-Kirchner M, Binder G, Schönherr N. Broad clinical spectrum in Silver-Russell syndrome and consequences for genetic testing in growth retardation. *Pediatrics* 2009;**123**:e929-31.

22. **Scott RH**, Douglas J, Baskcomb L, Nygren AO, Birch JM, Cole TR, Cormier-Daire V, Eastwood DM, Garcia-Minaur S, Lupunzina P, Tatton-Brown K, Blik J, Maher E, Rahman N. Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) robustly detects and distinguishes 11p15 abnormalities associated with overgrowth and growth retardation. *J Med Genet* 2008;**45**:106-113.
23. **Alders M**, Blik J, vd Lip K, vd Bogaard R, Mannens M. Determination of KCNQ1OT1 and H19 methylation levels in BWS and SRS patients using methylation-sensitive high-resolution melting analysis. *Eur J Hum Genet* 2009;**17**:467-73.
24. **Blik J**, Verde G, Callaway J, Maas S, De Crescenzo A, Sparago A, Cerrato F, Russo S, Ferraiuolo S, Rinaldi M, Fischetto R, Lalatta F, Giordano L, Ferrari P, Cubellis M, Larizza L, Temple IK, Mannens M, Mackay DJG, Riccio A. Hypomethylation at multiple maternally methylated imprinted regions including PLAGL1 and GNAS loci in Beckwith-Wiedemann syndrome. *Eur J Hum Genet* 2008;**17**:611-619.
25. **Bullman H**, Lever M, Robinson DO, Mackay DJ, Holder SE, Wakeling EL. Mosaic maternal uniparental disomy of chromosome 11 in a patient with Silver-Russell syndrome. *J Med Genet*. 2008;**45**:396-9.
26. **Lai KYC**, Skuse D, Stanhope R, Hindmarsh P. Cognitive abilities associated with the Silver-Russell syndrome. *Arch Dis Child* 1994;**71**:490-6.
27. **Feuk L**, Kalervo A, Lipsanen-Nyman M, Skaug J, Nakabayashi K, Finucane B, et al. Absence of a paternally inherited FOXP2 gene in developmental verbal dyspraxia. *Am J Hum Genet* 2006 Nov;**79**(5):965-72.
28. **Anderson J**, Viskochil D, O'Gorman M, Gonzales C. Gastrointestinal complications of Russell-Silver syndrome: a pilot study. *Am J Med Genet* 2002;**113**:15-9.
29. **Guettard E**, Portnoi M-F, Lohmann-Hedrich K, Keren B, Rossignol S, Winkler S, Kamel I, Leu S, Apartis E, Vidailhet, Klein C, Roze E. Myoclonus-dystonia due to maternal uniparental disomy. *Arch Neurol* 2008;**65**:1380-5.
30. **Carbon M**, Niethammer M, Peng S, Raymond D, Dhawan V, Chaly T, Ma Y, Bressman S, Eidelberg D Abnormal striatal and thalamic dopamine neurotransmission: Genotype-related features of dystonia. *Neurology* 2009;**72**:2097-103.
31. **Engel J**, Smallwood A, Harper A, Higgins MJ, Oshimura M, Reik W, Schofield PN, Maher ER. Epigenotype-phenotype correlations in Beckwith-Wiedemann syndrome. *J Med Genet* 2000;**37**:921-6.
32. **Azzi S**, Rossignol S, Steunou V, Sas T, Thibaud N, Danton F, Le Jule M, Heinrichs C, Cabrol S, Gicquel C, Le Bouc Y, Netchine I. Multilocus methylation analysis in a large cohort of 11p15-related foetal growth disorders (Russell Silver and Beckwith Wiedemann

- syndromes) reveals simultaneous loss of methylation at paternal and maternal imprinted loci. *Hum Mol Genet* 2009; **18**:4724-33.
33. **Maher ER**. Imprinting and assisted reproductive technology. *Hum Mol Genet* 2005; **14**:133-8.
34. **Svensson J**, Bjornstahl A, Ivarsson SA. Increased risk of Silver-Russell syndrome after in vitro fertilization? *Acta Paediatr* 2005;**94**:1163-5.
35. **Schieve LA**, Meikle SF, Ferre C, Peterson HB, Jeng G, Wilcox LS. Low and very low birth weight in infants conceived with use of assisted reproductive technology. *N Engl J Med*. 2002;**346**:731-7.
36. **Doornbos ME**, Maas SM, McDonnell J, Vermeiden JP, Hennekam RC. Infertility, assisted reproduction technologies and imprinting disturbances: a Dutch study. *Hum Reprod*. 2007;**22**:2476-80.
37. **Barker DJ**, Hales CN. Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. *Diabetologia*. 1992;**35**:595-601.
38. **Bruce S**, Hannula-Jouppi K, Puoskari M, Fransson I, Simola KO, Lipsanen-Nyman M, Kere J. Submicroscopic genomic alterations in Silver-Russell syndrome and Silver-Russell-like patients. *J Med Genet*. 2009 Sep 14. [Epub ahead of print].

FIGURE/TABLE HEADINGS

Figure 1: Facial appearance of individuals with ICR1 hypomethylation at different ages. Group A: 1.4 to 3.3 years; group B: 3.3 to 4.7 years; group C: 5.9 to 9.5 years; group D: 9.8 to 26.6 years.

Figure 2: Facial appearance of individuals with mUPD7 with increasing age. Group A: 1.3 to 3.8 years; group B: 4.0 to 7.9 years; group C: 10.0 to 14.2 years.

Informed consent was obtained from all patients/parents for publication of photographs

Table 1: Clinical features in SRS patients with ICR1 hypomethylation and mUPD7

	ICR1 hypomethylation (n=44)	mUPD7 (n=20)	P-value
<i>Epidemiology</i>			
Male Sex	50%	25%	0.10
Age (yr) - Median (IQR)	3.6 (1.8, 8.4)	6.4 (3.6, 10.1)	0.08
Maternal age (yr) - Mean (SD)	30.4 (4.6)	33.8 (6.3)	0.02
Paternal age (yr) - Mean (SD)	33.6 (5.9)	36.3 (6.9)	0.13
<i>Pregnancy</i>			
History of infertility	18%	20%	1.00
Assisted reproductive technology	11%	0%	0.31
Placental abnormality	35%	8%	0.08
<i>Growth</i>			
Birth weight \leq -2 SD	82%	70%	0.34
Height at examination \leq -2 SD	57%	65%	0.59
Relative macrocephaly*	70%	90%	0.12
Asymmetry	68%	30%	0.006
Face	48%	15%	0.01
Limbs	34%	10%	0.07
<i>Development</i>			
Global delay	20%	65%	0.001
Mild	11%	55%	
Moderate	2%	10%	
Delayed motor milestones	26% (n=34)**	7% (n=14)**	0.66
Speech delay	39%	50%	0.43
Speech therapy (if \geq 2.5 yr)	32% (n=28)	67% (n=18)	0.03
Statement of education (if \geq 3.5 yr)	9% (n=23)	25% (n=16)	0.21
Behavioural problems	9%	20%	0.24
<i>Congenital abnormalities</i>			
Cleft palate/ bifid uvula	7%	0%	0.55
Congenital heart defect	9%	0%	0.30
Male genital anomaly	23% (n=22)	0% (n=5)	0.55
Renal anomaly	0%	10%	0.09
Scoliosis	9%	5%	1.00
Other skeletal abnormality	9%	0%	0.30
<i>Other problems</i>			
Excessive sweating	64%	75%	0.41
Hypoglycaemia	24% (n=37)	29% (n=17)	0.75
Feeding difficulties	84%	90%	0.71
Gastroesophageal reflux	14%	10%	1.00
Otitis media	14%	20%	0.71
Delayed closure of fontanelles	43% (n=28)	36% (n=11)	1.00
Movement disorder	0%	15%	0.03
<i>Craniofacial features</i>			
Triangular face	59%	90%	0.02
Frontal bossing	60%	60%	1.00
Micro/retrognathia	64%	35%	0.06
Irregular/ crowded teeth	36%	45%	0.59
Small teeth	11%	20%	0.44
Down-turned corners of mouth	30%	20%	0.55
Thin upper lip	27%	30%	1.00
Low set/posteriorly rotated ears	36%	75%	0.007
<i>Other clinical signs</i>			
5 th finger clinodactyly	75%	45%	0.03
2/3 toe syndactyly	23%	20%	1.00
Camptodactyly	16%	25%	0.49
Joint contractures	11%	0%	0.31
Café au lait patches	14%	15%	1.00

*Head circumference \geq 1 SDS above length SDS, measured at age of examination.

** Excluding those with global developmental delay

Table 2: Congenital anomalies in SRS patients with ICR1 hypomethylation and mUPD7


Anomaly	ICR1 hypomethylation n=44	mUPD7 n=20
Palate	Cleft palate (2)* Bifid uvula (2) Palatal insufficiency (1) Ankyloglossia (1)	
Heart	Ventricular septal defect (3) Atrial septal defect (1) Patent ductus arteriosus (1)	
Male genital	Bilateral undescended testes (3) Hypospadias (1)	
Renal		Horseshoe kidney (1) Unilateral renal dysplasia (1)
Skeletal	Scoliosis (4) Hip dysplasia (2) Talipes equinovarus (1) Radial hypoplasia, absent thumbs (1) Limited elbow supination (1)	Scoliosis (1)
Other	Iris coloboma (1) Ileal insufficiency (1)	


* Including patient with mosaic mUPD11²⁵

Table 3: Correlation of level of ICR1 hypomethylation with clinical severity

Clinical Variable	Correlation coefficient	P-value
Clinical score**	-0.12	0.53
Birth weight*	0.16	0.41
Postnatal height*	0.15	0.42
Feeding difficulties**	-0.34	0.07
Congenital abnormality [†]	ND	0.35
Asymmetry [†]	ND	0.71
Global developmental delay [†]	ND	0.37

Analysis using Pearson correlation (*), Spearman's rank correlation (**) or unpaired t-test ([†]).
 ND: not determined.



A**B****C**